Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA.
J Allergy Clin Immunol. 2011 Mar;127(3):741-9. doi: 10.1016/j.jaci.2010.12.010.
The mechanisms and consequences of the observed association between obesity and childhood asthma are unclear.
We sought to determine the effect of obesity on treatment responses to inhaled corticosteroids in asthmatic children.
We performed a post hoc analysis to evaluate the interaction between body mass index (BMI) and treatment with inhaled budesonide on lung function in the Childhood Asthma Management Program trial. Participants were then stratified into overweight/obese and nonoverweight groups, and their response to inhaled budesonide was analyzed longitudinally over the 4 years of the trial.
There was a significant interaction between BMI and budesonide for prebronchodilator FEV(1)/forced vital capacity (FVC) ratio (P = .0007) and bronchodilator response (BDR; P = .049) and a nonsignificant trend for an interaction between BMI and budesonide on prebronchodilator FEV(1) (P = .15). Nonoverweight children showed significant improvement with inhaled budesonide in lung function (FEV(1), FEV(1)/FVC ratio, and BDR) during the early (years 1-2) and late (years 3-4) stages of the trial. Overweight/obese children had improved FEV(1) and BDR during the early but not the late stage of the trial and showed no improvement in FEV(1)/FVC ratio. When comparing time points at which both groups showed a significant response, the degree of improvement among nonoverweight children was significantly greater than in overweight/obese children at most visits. Nonoverweight children had a 44% reduction in the risk of emergency department visits or hospitalizations throughout the trial (P = .001); there was no reduction in risk among overweight/obese children (P = .97).
Compared with children of normal weight, overweight/obese children in the Childhood Asthma Management Program showed a decreased response to inhaled budesonide on measures of lung function and emergency department visits/hospitalizations for asthma.
肥胖与儿童哮喘之间观察到的关联的机制和后果尚不清楚。
我们旨在确定肥胖对哮喘儿童吸入皮质类固醇治疗反应的影响。
我们进行了一项事后分析,以评估体质指数(BMI)与吸入布地奈德治疗之间在儿童哮喘管理计划试验中对肺功能的相互作用。然后,将参与者分为超重/肥胖和非超重/肥胖两组,并在试验的 4 年内对他们吸入布地奈德的反应进行纵向分析。
BMI 与布地奈德对预支气管扩张剂 FEV1/FVC 比值(P=0.0007)和支气管扩张剂反应(BDR;P=0.049)有显著的交互作用,BMI 与布地奈德对预支气管扩张剂 FEV1(P=0.15)有非显著的趋势交互作用。非超重儿童在试验的早期(第 1-2 年)和晚期(第 3-4 年)吸入布地奈德后肺功能(FEV1、FEV1/FVC 比值和 BDR)显著改善。超重/肥胖儿童在试验的早期而非晚期 FEV1 和 BDR 有所改善,而 FEV1/FVC 比值没有改善。当比较两组均显示出显著反应的时间点时,在大多数就诊时,非超重儿童的改善程度明显大于超重/肥胖儿童。非超重儿童在整个试验期间急诊就诊或住院的风险降低了 44%(P=0.001);超重/肥胖儿童的风险没有降低(P=0.97)。
与体重正常的儿童相比,儿童哮喘管理计划中的超重/肥胖儿童对肺功能和因哮喘而急诊就诊/住院的测量指标对吸入布地奈德的反应降低。